Citations

Citations to this article as recorded by  

• Pathogenic Mechanisms of Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)-Associated Hepatocellular Carcinoma
  Toru Nakamura, Atsutaka Masuda, Dan Nakano, Keisuke Amano, Tomoya Sano, Masahito Nakano, Takumi Kawaguchi
  Cells.2025; 14(6): 428.     CrossRef
• The Impact of Rifaximin on Hepatic Encephalopathy during Lenvatinib Therapy in Patients with Hepatocellular Carcinoma and Splenorenal Shunt
  Shigeo Shimose, Hideki Iwamoto, Takashi Niizeki, Tomotake Shirono, Etsuko Moriyama, Takumi Kawaguchi
  Internal Medicine.2025;[Epub]     CrossRef
• Metabolic dysfunction-associated fatty liver disease is a ubiquitous latent cofactor in viral- and alcoholic-related hepatocellular carcinoma: Editorial on “Global prevalence of metabolic dysfunction-associated fatty liver disease-related hepatocellular c
  Toru Nakamura, Masahito Nakano, Tsubasa Tsutsumi, Keisuke Amano, Takumi Kawaguchi
  Clinical and Molecular Hepatology.2024; 30(4): 705.     CrossRef
• Interaction between sarcopenia and nonalcoholic fatty liver disease
  Sae Kyung Joo, Won Kim
  Clinical and Molecular Hepatology.2023; 29(Suppl): S68.     CrossRef
• An ultrasensitive photoelectrochemical assay for tumor necrosis factor-alpha based on hollow CdS cubes as a signal generator and NiCo2O4-Au as a signal extinguisher
  Yamin Fu, Baohuan Fan, Shenzhen Chang, Dongyu Guo, Fuxiang Wang, Qinhe Pan
  The Analyst.2023; 148(19): 4746.     CrossRef
• Role of increased intestinal permeability in the development and progression of liver diseases
  S. N. Mekhtiyev, O. A. Mekhtiyeva, O. M. Berko, A. M. Kolodkin
  Experimental and Clinical Gastroenterology.2023; (12): 130.     CrossRef